STREAMER : STent Restenosis And MEdicaments Release

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a pilot study to evaluate the feasibility and the efficiency of local delivery of paclitaxel after stenting of long femoropopliteal arterial lesions TASC C and D before the realization of a large randomized multicentric study. Patients concerned are in critical ischemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospices Civils de Lyon
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• patients with critical ischemia of a lower limb with ankle pressure < 50 mmHg

• lesions TASC C and D of the superficial femoral or popliteal artery

Exclusion Criteria:

• patient allergic to paclitaxel

• patient with a cancer, a neutropenia, with immunosuppressor medicament or chemotherapy

• patient with contraindication to take 2 anti-aggregants platelets